세계의 항인지질 증후군 치료 시장 보고서(2025년)
Antiphospholipid Syndrome Treatment Global Market Report 2025
상품코드 : 1824579
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 항인지질 증후군 치료 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년 연평균 복합 성장률(CAGR)은 11.0%로 확대되어 800억 2,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 제약산업의 지속적인 확대, 지속가능한 염료 및 안료 수요 증가, 천연 및 유기화장품 수요 증가, 농약 솔루션의 요구 증가, 커스터마이즈 솔루션 수요 증가 등에 기인합니다. 예측기간의 세계 동향으로는 섬유산업의 혁신, 사진 산업의 기술진보, 폴리우레탄 용도의 혁신, 생산공정의 기술진보, 제조거점의 세계적 시프트 등이 있습니다.

향후 5년간의 성장률 11.0%라는 예측은 이 시장의 지난 예측으로부터 0.3% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 프랑스와 벨기에에서 개발된 직접 경구 항응고인자 및 루푸스 항응고인자 검사 시약의 가격을 상승시켜 응고 위험의 장기화와 혈전증 관리 비용의 상승을 초래하여 미국의 혈액 의료에 지장을 초래할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

자가면역 질환 증가가 예상되며, 항인지질 증후군 치료 시장의 성장을 견인합니다. 자가면역질환에는 비정상적인 면역반응이 관여하고 있어 신체가 실수로 자신의 조직을 공격해 버립니다. 이러한 자가면역 질환 중 하나에 항인지질 증후군(APS)이 있으며, 과민성 장 증후군(IBS) 등 소화기계의 합병증을 동반할 수 있습니다. 일례로 Crohn's and Colitis Canada는 2023년 6월에 APS를 포함한 염증성 장질환(IBD)을 앓고 있는 것으로 추정되는 캐나다인은 32만 2,600명을 넘는 것으로 보고하고 있으며, 이 수는 자가면역질환의 유병률 상승을 반영해 2035년까지 약 47만명으로 증가할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Antiphospholipid syndrome treatment involves medical interventions and therapies aimed at managing and alleviating the complications associated with antiphospholipid syndrome-a chronic autoimmune disorder characterized by the presence of antiphospholipid antibodies in the blood. These antibodies can elevate the risk of abnormal blood clot formation, leading to complications such as thrombosis, pregnancy-related issues, and organ damage.

The primary healthcare and laboratory labels materials are nylon, polyester, polyolefin, vinyl, paper, and others. Nylon, a synthetic polyamide material, is valued for its strength, toughness, and elasticity. Produced through polymerization, nylon exhibits flexibility, a high melting point, and finds applications across diverse industrial and consumer domains. Technologies such as thermal transfer, direct thermal, laser, and inkjet are employed, catering to end-users such as pharmaceuticals, nutraceuticals, medical devices, blood banks, hospital services, and laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The healthcare and laboratory labels market research report is one of a series of new reports from The Business Research Company that provides healthcare and laboratory labels market statistics, including healthcare and laboratory labels industry global market size, regional shares, competitors with a healthcare and laboratory labels market share, detailed healthcare and laboratory labels market segments, market trends and opportunities, and any further data you may need to thrive in the healthcare and laboratory labels industry. This healthcare and laboratory labels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiphospholipid syndrome treatment market size has grown rapidly in recent years. It will grow from $47.83 billion in 2024 to $52.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to pharmaceutical industry growth, dye and pigment manufacturing, photographic chemicals production, polyurethane industry, hair dye and cosmetic products.

The antiphospholipid syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $80.02 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to continued pharmaceutical industry expansion, growing demand for sustainable dyes and pigments, rising demand for natural and organic cosmetics, increased need for agrochemical solution, rise in demand for customized solutions. Major trends in the forecast period include textile industry innovation, technological advancements in photographic industry, innovation in polyurethane applications, technological advancements in production processes, global shifts in manufacturing hubs.

The forecast of 11.0% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. hematology care by inflating prices of direct oral anticoagulants and lupus anticoagulant testing reagents developed in France and Belgium, resulting in prolonged clotting risk and higher thrombophilia management costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in autoimmune disorders is set to drive the growth of the market for antiphospholipid syndrome treatment. Autoimmune disorders involve abnormal immune responses, leading to the body mistakenly attacking its own tissues. One such autoimmune condition is Antiphospholipid Syndrome (APS), which can involve digestive system complications, including irritable bowel syndrome (IBS). As an example, Crohn's and Colitis Canada reported in June 2023 that over 322,600 Canadians were estimated to have inflammatory bowel diseases (IBD), including APS, and this number is expected to increase to around 470,000 by 2035, reflecting the rising prevalence of autoimmune disorders.

The growth of the antiphospholipid syndrome treatment market is further propelled by the increasing healthcare expenditure. Adequate healthcare spending is crucial for comprehensive treatment, covering medications, monitoring tests, and specialty care for effective management and enhanced quality of life for patients. As of December 2023, the Centers for Medicare And Medicaid Services noted a 4.1% increase in national health expenditures in the United States, reaching $4.5 trillion in 2022. This expenditure is vital for supporting various healthcare needs, including the treatment of autoimmune disorders such as APS.

Major companies in the antiphospholipid syndrome treatment market are focusing on developing novel anticoagulants. These medications, such as tecarfarin, are designed to prevent blood clot formation and work differently from traditional anticoagulants such as warfarin. For example, Cadrenal Therapeutics Inc. expanded its evaluation of tecarfarin in August 2023 as a potential treatment for patients with APS. Tecarfarin, a reversible anticoagulant, has undergone multiple human clinical trials, showing promise as an alternative treatment option for APS.

Leading companies in the car covers market are innovating products, such as immunoglobulin reagents, to improve the accuracy and reliability of diagnostic tests. Immunoglobulin reagents are laboratory instruments that contain antibodies designed to detect, quantify, or analyze specific antigens in diagnostic and research contexts. For example, in February 2024, Werfen, a Spain-based diagnostics company, announced the CE mark for its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents. The distinguishing feature of the Aptiva APS IgG and APS IgM reagents is their use of Aptiva particle-based multi-analyte technology (PMAT) for the semi-quantitative detection of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aB2GP1) IgG and IgM autoantibodies in human serum and citrated plasma. This technology serves as a valuable tool for diagnosing primary and secondary antiphospholipid syndrome (APS) when used in conjunction with other laboratory findings.

Major companies operating in the antiphospholipid syndrome treatment market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Bristol Myers Squibb, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Cipla Ltd., Baxter International, Teva Pharmaceutical Industries Ltd., CSL Limited, Boehringer Ingelheim International GmbH, Fresenius Kabi, EisaiCo. Ltd., Aurobindo Pharma, Dr. Reddy's Laboratories, Hikma Pharmaceutics PLC, Aspen Pharmacare, Zydus Lifesciences Limited, Sawai Pharmaceutical Co. Ltd., Leo Pharma, Daiichi Sankyo Company

North America was the largest region in the antiphospholipid syndrome treatment market in 2024. The regions covered in the antiphospholipid syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antiphospholipid syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antiphospholipid syndrome treatment market consists of revenues earned by entities by providing services such as surgeries, diagnosis tests, physical examinations, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The antiphospholipid syndrome treatment market also includes sales of pentosan polysulfate sodium, aspirin, dimethyl sulfoxide, heparin, and warfarin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antiphospholipid Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiphospholipid syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for antiphospholipid syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antiphospholipid syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Antiphospholipid Syndrome Treatment Market Characteristics

3. Antiphospholipid Syndrome Treatment Market Trends And Strategies

4. Antiphospholipid Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Antiphospholipid Syndrome Treatment Growth Analysis And Strategic Analysis Framework

6. Antiphospholipid Syndrome Treatment Market Segmentation

7. Antiphospholipid Syndrome Treatment Market Regional And Country Analysis

8. Asia-Pacific Antiphospholipid Syndrome Treatment Market

9. China Antiphospholipid Syndrome Treatment Market

10. India Antiphospholipid Syndrome Treatment Market

11. Japan Antiphospholipid Syndrome Treatment Market

12. Australia Antiphospholipid Syndrome Treatment Market

13. Indonesia Antiphospholipid Syndrome Treatment Market

14. South Korea Antiphospholipid Syndrome Treatment Market

15. Western Europe Antiphospholipid Syndrome Treatment Market

16. UK Antiphospholipid Syndrome Treatment Market

17. Germany Antiphospholipid Syndrome Treatment Market

18. France Antiphospholipid Syndrome Treatment Market

19. Italy Antiphospholipid Syndrome Treatment Market

20. Spain Antiphospholipid Syndrome Treatment Market

21. Eastern Europe Antiphospholipid Syndrome Treatment Market

22. Russia Antiphospholipid Syndrome Treatment Market

23. North America Antiphospholipid Syndrome Treatment Market

24. USA Antiphospholipid Syndrome Treatment Market

25. Canada Antiphospholipid Syndrome Treatment Market

26. South America Antiphospholipid Syndrome Treatment Market

27. Brazil Antiphospholipid Syndrome Treatment Market

28. Middle East Antiphospholipid Syndrome Treatment Market

29. Africa Antiphospholipid Syndrome Treatment Market

30. Antiphospholipid Syndrome Treatment Market Competitive Landscape And Company Profiles

31. Antiphospholipid Syndrome Treatment Market Other Major And Innovative Companies

32. Global Antiphospholipid Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antiphospholipid Syndrome Treatment Market

34. Recent Developments In The Antiphospholipid Syndrome Treatment Market

35. Antiphospholipid Syndrome Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기